Single Dose of pGM169/GL67A in CF Patients

Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis

The study objectives are to assess safety, tolerability and gene expression after a single dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of patients with cystic fibrosis.

Study Overview

• Status: Completed
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Drug: pGM169/GL67A

Detailed Description

The trial is designed as single administration to nose and lung. Initially, in Part A, 3 patients will be dosed individually one week apart with 10 ml (26.5mg pDNA) via nebuliser and a nasal dose equivalent to 10% of this (based on relative surface area calculations: conducting airways approximate 540 cm2; nasal epithelium from both nostrils approximately 40 cm2). Based on our previous study, we do not expect any side effects of the nasal dose, but we are taking this opportunity, as this group will not be undergoing bronchoscopic efficacy measures, to assess gene transfer to the nasal epithelium. A further group of 3 patients will then be treated in exactly the same way with 20 ml nebulised and a 2 ml nasal dose.

Subsequently, patients will receive doses of 2 ml (nasal) and 20 ml (nebulised). These patients will undergo more intensive monitoring for gene expression both before and after administration.

In Part B of the protocol, we will test combinations of delivery conditions and dose in an attempt to identify the maximal tolerated dose. We may also use Ibuprofen or Prednisolone in standard clinical doses around the dosing period to reduce the inflammatory response. Delivery conditions include: standard nebulisation (each 5 ml over 25 minutes as in Part A), slow (each 5 ml over 75-150 minutes) and divided (standard rate delivery with a period of up to 6 hours between aliquots). With these conditions we will test the following doses until a tolerable dose is reached: 20 ml (no standard delivery as sufficient data already available from Part A); 10 ml; 5 ml; 2.5 ml. Each dosing strategy will initially be performed in a cohort of 3 patients although numbers may need to be increased to 6 if data are inconclusive. Once a satisfactory Single dose of pGM169/GL67A in CF patients; cro851 Version 10; 16.08.2010 10 dose and nebulisation strategy has been identified, the numbers receiving this will be increased to 6. The maximum number of patients recruited to this arm of the study will be 30. Part B will also allow either these subjects or others to receive a 2 ml nasal dose with both pre and post-measurements of nasal PD.

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SW3 6NP
    • Royal Brompton Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 70 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Cystic fibrosis confirmed by sweat testing or genetic analysis
• Males and females aged 16 years and above
• Forced expiratory volume in the 1st second (FEV1) > 60% predicted values
• Clinical stability at entry
• Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter
• If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose
• Written informed consent obtained
• Permission to inform GP of participation in study

Exclusion Criteria:

• Infection with Burkholderia cepacia complex organisms or MRSA
• Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds)
• Acute upper respiratory tract infection within the last 2 weeks
• Previous spontaneous pneumothorax without pleurodesis
• Recurrent severe haemoptysis
• Current smoker

• Significant comorbidity including:

  1. Moderate/severe CF liver disease
  2. Significant renal impairment
  3. Significant coagulopathy
• Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations
• Pregnant or breastfeeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 20ml pGM169/GL67A; Received a nebulized dose 20ml via an breath-actuated nebulizer	Drug: pGM169/GL67A; Received a nebulized dose via an breath-actuated nebulizer; Other Names: 5ml pGM169/GL67A, 10ml pGM169/GL67A and 20ml pGM169/GL67A
Experimental: 10ml pGM169/GL67A; Received a nebulized dose 10ml via an breath-actuated nebulizer	Drug: pGM169/GL67A; Received a nebulized dose via an breath-actuated nebulizer; Other Names: 5ml pGM169/GL67A, 10ml pGM169/GL67A and 20ml pGM169/GL67A
Experimental: 5ml pGM169/GL67A; Received a nebulized dose 5ml via an breath-actuated nebulizer	Drug: pGM169/GL67A; Received a nebulized dose via an breath-actuated nebulizer; Other Names: 5ml pGM169/GL67A, 10ml pGM169/GL67A and 20ml pGM169/GL67A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body Maximum Temperature		6-8h
Blood Leukocytes	Blood leukocytes measure	8h
Blood Neutrophils	Blood neutrophils measures	8h
FEV1 Relative % Drop	FEV1 relative % drop measure	8h
FVC Relative % Drop	FVC relative % drop measure	6h
Lung Clearance Index - LCI	Lung clearance index measure is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout technique.	8h

Collaborators and Investigators

• Sponsor: Imperial College London
• Collaborators: University of Pennsylvania; University of Oxford; University of Edinburgh; Royal Brompton & Harefield NHS Foundation Trust; Cystic Fibrosis Trust
• Investigators: Study Director: Eric Alton, Imperial College London; Principal Investigator: Jane C Davies, Imperial College London; Principal Investigator: Uta Griesenbach, Imperial College London; Principal Investigator: Steve Hyde, University of Oxford; Principal Investigator: Deborah Gill, University of Oxford; Principal Investigator: David Porteous, Edinburgh University; Principal Investigator: Chris Boyd, Edinburgh University; Principal Investigator: Alastair Innes, Edinburgh University

Publications and helpful links

General Publications

• Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947-54. doi: 10.1016/s0140-6736(98)06532-5.
• Alton EW, Boyd AC, Porteous DJ, Davies G, Davies JC, Griesenbach U, Higgins TE, Gill DR, Hyde SC, Innes JA; UK Cystic Fibrosis Gene Therapy Consortium *. A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1389-92. doi: 10.1164/rccm.201506-1193LE. No abstract available.

Helpful Links

• UK CF Gene Therapy Consortium website

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2008
• Primary Completion (Actual): August 1, 2009
• Study Completion (Actual): December 1, 2010

Study Registration Dates

• First Submitted: November 11, 2008
• First Submitted That Met QC Criteria: November 11, 2008
• First Posted (Estimate): November 13, 2008

Study Record Updates

• Last Update Posted (Actual): January 18, 2020
• Last Update Submitted That Met QC Criteria: January 9, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Safety; Cystic fibrosis; Tolerability; Gene expression; Single dose; Pilot; CFTR gene; Non-viral
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis
• Other Study ID Numbers: cro851

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No